Palisade Bio, Inc. (PALI)

6.94 -0.12 (-1.70%) 收市：04:00PM EDT

Palisade Bio, Inc.

7750 El Camino Real
Suite 2A
Carlsbad, CA 92009
United States
858 704 4900
https://www.palisadebio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 9

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. J. D. Finley	CEO, CFO & Director	791.33k	無	1958
Dr. Mitchell Lawrence Jones M.D., Ph.D.	COO & Chief Medical Officer	635k	無	1978
Mr. Ryker Willie	Senior VP of Finance & Corporate Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

公司管治

截至 無 止，Palisade Bio, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。